Novel ultra-long-acting biologic depemokimab reduced nasal polyps in chronic rhinosinusitis, two parallel phase III trials ...

Tezepelumab (Tezspire) reduced nasal polyps and symptoms in severe chronic rhinosinusitis while also decreasing need for ...

FDA reviews GSK depemokimab for asthma and CRSwNP, with a decision expected by December 2025. Phase 3 data shows improvements ...

Treatment with tezepelumab has been effective for sinonasal symptoms in patients with severe, uncontrolled asthma and a ...

An international collaboration of researchers, sponsored by GSK and working on behalf of the ANCHOR-1 and ANCHOR-2 trial ...

The Food and Drug Administration (FDA) has approved neffy ® (epinephrine nasal spray) 1mg for the emergency treatment of type 1 allergic reactions, including anaphylaxis, in pediatric patients aged 4 ...

With Sunday’s Academy Awards ceremony in the rearview mirror, GSK is looking ahead to a potential blockbuster premiere of its ...

The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for depemokimab for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps ...

An asthma drug has shown positive results when used to treat nasal polyps, researchers have said. Tezepelumab was first approved for treating asthma in 2021, but new research led by a University ...

Opens in a new tab or window SAN DIEGO -- Novel ultra-long-acting biologic depemokimab reduced nasal polyps in chronic rhinosinusitis, two parallel phase III trials showed. Twice-yearly injections ...